Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib—Report of Three Cases

Pazopanib is a potent multi-kinase inhibitor that hinders angiogenesis and blocks tumor growth. It has been approved for the treatment of metastatic renal cell carcinoma (mRCC) and advanced soft tissue sarcoma. There is emerging evidence that bleeding is a common adverse effect of pazopanib and othe...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Erofili Papadopoulou, Emmanouil Vardas, Styliani Tziveleka, Maria Georgaki, Maria Kouri, Konstantinos Katoumas, Evangelia Piperi, Nikolaos G. Nikitakis
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	MDPI AG 2022-12-01
Reeks:	Dentistry Journal
Onderwerpen:	pazopanib angiogenesis inhibitors gingival bleeding jaw osteonecrosis oral side effects metastatic renal cell carcinoma
Online toegang:	https://www.mdpi.com/2304-6767/10/12/232
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!